The DOI matches its Crossref record.
Antidepressants and suicide: risk–benefit conundrums
Open accessAbstract
There has been a long-standing controversy about the possibility that selective serotonin reuptake inhibitor (SSRI) antidepressants might induce suicidality in some patients. To shed light on this issue, this paper reviews available randomized controlled trials (RCTs), meta-analyses of clinical trials and epidemiological studies that have been undertaken to investigate the issue further. The original clinical studies raising concerns about SSRIs and suicide induction produced evidence of a dose-dependent link on a challenge- dechallenge and rechallenge basis between SSRIs and both agitation and suicidality. Meta-analyses of RCTs conducted around this time indicated that SSRIs may reduce suicidal ideation in some patients. These same RCTs, however, revealed an excess of suicidal acts on active treatments compared with placebo, with an odds ratio of 2.4 (95% confidence interval 1.6–3.7). This excess of suicidal acts also appears in epidemiological studies. The data reviewed here make it difficult to sustain a null hypothesis that SSRIs do not cause problems in some individuals. Further studies or further access to data are indicated to establish the magnitude of any risk and the characteristics of patients who may be most at risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Fergusson, D., Doucette, S., Glass, K. C., Shapiro, S., Healy, D., Hebert, P., & Hutton, B. (2005) · BMJ · doi:10.1136/bmj.330.7488.396 · Cited by 510
Self-citationBauer, M., Bschor, T., Pfennig, A., Whybrow, P. C., Angst, J., Versiani, M., Möller, H.-J., WFSBP Task Force on Unipolar Depres, Bauer, M., Bschor, T., et al. (2007) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701227829 · Cited by 477
Sleep disturbances and suicide risk: A review of the literature
Bernert, R. A. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s1248 · Cited by 259
Essentials of clinical hypnosis: An evidence-based approach.
Lynn, S. J., & Kirsch, I. (2006) · doi:10.1037/11365-000 · Cited by 174
Antidepressant dose, age, and the risk of deliberate self-harm
Miller, M., Swanson, S. A., Azrael, D., Pate, V., & Stürmer, T. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.1053 · Cited by 92
A systematic review of long-term studies of drug treated and non-drug treated depression
Hughes, S., & Cohen, D. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.027 · Cited by 71
Selective serotonin reuptake inhibitors and suicidal behaviour: a population-based cohort study
Lagerberg, T., Fazel, S., Sjölander, A., Hellner, C., Lichtenstein, P., & Chang, Z. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-021-01179-z · Cited by 61
Antidepressants and Suicide Risk: A Comprehensive Overview
Pompili, M., Serafini, G., Innamorati, M., Ambrosi, E., Giordano, G., Girardi, P., Tatarelli, R., & Lester, D. (2010) · Pharmaceuticals · doi:10.3390/ph3092861 · Cited by 53
Iosifescu, D. V., Greenwald, S., Devlin, P., Perlis, R. H., Denninger, J. W., Alpert, J. E., & Fava, M. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01156.x · Cited by 44
Mental health care for adults with suicide ideation
Brook, R., Klap, R., Liao, D., & Wells, K. B. (2006) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2006.01.001 · Cited by 43
Challenging the promotion of antidepressants for nonsevere depression
Braillon, A., Lexchin, J., Noble, J. H., Menkes, D., M'sahli, L., Fierlbeck, K., Blumsohn, A., & Naudet, F. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13010 · Cited by 16
High-Dose Benzodiazepine Use among Long-Term Users: When Will We Ever Learn?
Zito, J. M. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000437374 · Cited by 7
Metadata
- Authors
- Healy, D., & Whitaker, C.
- Venue
- Journal of Psychiatry and Neuroscience
- Publisher
- Canadian Science Publishing
- Published
- 2003-09
- Volume
- 28
- Issue
- 5
- Pages
- 331-337
- ISSN
- 1180-4882 (ISSN-L)
- 1488-2434
- OpenAlex
- W57303692
- Cited by
- 172
- References
- 0
- FWCI
- 23.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.